ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
Sep 23, 2024 · Sanofi’s tolebrutinib significantly delayed disability progression, by 31%, and increased the rates of disability improvement compared with a placebo in people with nonrelapsing secondary...
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Nov 5, 2024 · Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in...
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
Sep 20, 2024 · Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of...
Press Room - Sanofi US News
Sep 20, 2024 · Tolebrutinib is an investigational, oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase (BTK) inhibitor that achieves CSF concentrations predicted to modulate B lymphocytes and disease-associated microglia.
Tolebrutinib Looks Promising for Patients With Non-Relapsing …
Oct 15, 2024 · Tolebrutinib was found to delay disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), according to results from the HERCULES study.
Tolebrutinib Long-term Data Continue to Show the BTK Inhibitor …
Apr 25, 2023 · Tolebrutinib is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a...
Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT
Sep 2, 2024 · Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies,...
Feb 23, 2023 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key immune mediators that may drive disease progression within the CNS.
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
Sep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis.
ECTRIMS 2023: Tolebrutinib show benefits for up to 3 years
Oct 16, 2023 · Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS),...
- Some results have been removed